BRAF V600 MUTATION
Clinical trials for BRAF V600 MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRAF V600 MUTATION trials appear
Sign up with your email to follow new studies for BRAF V600 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can extra therapy after surgery keep melanoma from returning?
Disease control Recruiting nowThis study looks at whether giving extra treatment after surgery can lower the chance of melanoma coming back in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 adults will receive a combination of two drugs (encorafenib and binimetinib) befo…
Matched conditions: BRAF V600 MUTATION
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Can brain tumor patients safely reduce their medication? new study investigates
Disease control Recruiting nowThis study looks at whether people with a slow-growing brain tumor (low-grade glioma) that has a specific gene change (BRAF V600) can safely stop or lower their dose of two targeted drugs (dabrafenib and trametinib) after taking them for 12-24 months. About 96 participants will e…
Matched conditions: BRAF V600 MUTATION
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …
Matched conditions: BRAF V600 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated May 12, 2026 13:40 UTC